After acute coronary syndrome (ACS), inflammation aids healing but may harm the heart. Interleukin (IL)-18 and IL-1β are pivotal proinflammatory cytokines released during pyroptosis, a process that initiates and sustains inflammation. This study aimed to evaluate the levels of circulating IL-18 and IL-1β during the progression of ACS and to determine their association with subsequent clinical events in ACS patients.
Circulating levels of IL-18 and IL-1β are associated with subsequent clinical events in ACS patients.
Employing immunoassays, we examined plasma levels of IL-1β and IL-18 in 159 ACS patients and matched them with 159 healthy controls. The primary composite endpoint included recurrent unstable angina, myocardial infarction, heart failure exacerbation, stroke, or cardiovascular death.
ACS patients exhibited a significant increase in plasma IL-18 levels, measuring 6.36 [4.46-9.88] × 10 pg/mL, in contrast to the control group with levels at 4.04 [3.21-4.94] × 10 pg/mL (p 0.05).
IL-18 appears to hold potential as a predictive marker for anticipating clinical outcomes in patients with ACS.
© 2024 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.
